BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

459 related articles for article (PubMed ID: 33938795)

  • 21. Attainment and characteristics of clinical remission according to the new ACR-EULAR criteria in abatacept-treated patients with early rheumatoid arthritis: new analyses from the Abatacept study to Gauge Remission and joint damage progression in methotrexate (MTX)-naive patients with Early Erosive rheumatoid arthritis (AGREE).
    Smolen JS; Wollenhaupt J; Gomez-Reino JJ; Grassi W; Gaillez C; Poncet C; Le Bars M; Westhovens R
    Arthritis Res Ther; 2015 Jun; 17(1):157. PubMed ID: 26063454
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Risk factors for methotrexate-induced abnormal laboratory monitoring results in patients with rheumatoid arthritis.
    Kent PD; Luthra HS; Michet C
    J Rheumatol; 2004 Sep; 31(9):1727-31. PubMed ID: 15338491
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Six-month flare risk after discontinuing long-term methotrexate treatment in patients having rheumatoid arthritis with low disease activity.
    Lee JS; Oh JS; Hong S; Kim YG; Lee CK; Yoo B
    Int J Rheum Dis; 2020 Aug; 23(8):1076-1081. PubMed ID: 33021334
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Non-alcoholic steatohepatitis-like pattern in liver biopsy of rheumatoid arthritis patients with persistent transaminitis during low-dose methotrexate treatment.
    Mori S; Arima N; Ito M; Fujiyama S; Kamo Y; Ueki Y
    PLoS One; 2018; 13(8):e0203084. PubMed ID: 30142184
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tocilizumab is clinically, functionally, and radiographically effective and safe either with or without low-dose methotrexate in active rheumatoid arthritis patients with inadequate responses to DMARDs and/or TNF inhibitors: a single-center retrospective cohort study (KEIO-TCZ study) at week 52.
    Izumi K; Kaneko Y; Yasuoka H; Seta N; Kameda H; Kuwana M; Takeuchi T
    Mod Rheumatol; 2015 Jan; 25(1):31-7. PubMed ID: 24684408
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adverse effects of low dose methotrexate in rheumatoid arthritis patients.
    Gilani ST; Khan DA; Khan FA; Ahmed M
    J Coll Physicians Surg Pak; 2012 Feb; 22(2):101-4. PubMed ID: 22313647
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Security of the combined treatment of methotrexate and leflunomide in patients with rheumatoid arthritis].
    Nesa L; Gobbi C; Alba P; Exeni I; Babini A; Albiero E
    Rev Fac Cien Med Univ Nac Cordoba; 2007; 64(4):109-14. PubMed ID: 19928400
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The SMILE study -- safety of methotrexate in combination with leflunomide in rheumatoid arthritis.
    Bird P; Griffiths H; Tymms K; Nicholls D; Roberts L; Arnold M; Burnet S; de Jager J; Scott J; Zochling J; Littlejohn G
    J Rheumatol; 2013 Mar; 40(3):228-35. PubMed ID: 23322457
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tocilizumab inhibits structural joint damage and improves physical function in patients with rheumatoid arthritis and inadequate responses to methotrexate: LITHE study 2-year results.
    Fleischmann RM; Halland AM; Brzosko M; Burgos-Vargas R; Mela C; Vernon E; Kremer JM
    J Rheumatol; 2013 Feb; 40(2):113-26. PubMed ID: 23322466
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Assessment of liver fibrosis markers in people with rheumatoid arthritis on methotrexate.
    Olsson-White DA; Olynyk JK; Ayonrinde OT; Paramalingam S; Keen HI
    Intern Med J; 2022 Apr; 52(4):566-573. PubMed ID: 33135387
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Meta-Regression of a Dose-Response Relationship of Methotrexate in Mono- and Combination Therapy in Disease-Modifying Antirheumatic Drug-Naive Early Rheumatoid Arthritis Patients.
    Bergstra SA; Allaart CF; Stijnen T; Landewé RBM
    Arthritis Care Res (Hoboken); 2017 Oct; 69(10):1473-1483. PubMed ID: 27992656
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of combination therapy with methotrexate and sinomenine or leflunomide for active rheumatoid arthritis: A randomized controlled clinical trial.
    Huang RY; Pan HD; Wu JQ; Zhou H; Li ZG; Qiu P; Zhou YY; Chen XM; Xie ZX; Xiao Y; Huang QC; Liu L
    Phytomedicine; 2019 Apr; 57():403-410. PubMed ID: 30851515
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Determinants of red blood cell methotrexate polyglutamate concentrations in rheumatoid arthritis patients receiving long-term methotrexate treatment.
    Stamp LK; O'Donnell JL; Chapman PT; Zhang M; Frampton C; James J; Barclay ML
    Arthritis Rheum; 2009 Aug; 60(8):2248-56. PubMed ID: 19644853
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effectiveness of methotrexate with step-down glucocorticoid remission induction (COBRA Slim) versus other intensive treatment strategies for early rheumatoid arthritis in a treat-to-target approach: 1-year results of CareRA, a randomised pragmatic open-label superiority trial.
    Verschueren P; De Cock D; Corluy L; Joos R; Langenaken C; Taelman V; Raeman F; Ravelingien I; Vandevyvere K; Lenaerts J; Geens E; Geusens P; Vanhoof J; Durnez A; Remans J; Vander Cruyssen B; Van Essche E; Sileghem A; De Brabanter G; Joly J; Meyfroidt S; Van der Elst K; Westhovens R
    Ann Rheum Dis; 2017 Mar; 76(3):511-520. PubMed ID: 27432356
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Risk factors associated with the cumulative survival of low-dose methotrexate in 273 Japanese patients with rheumatoid arthritis.
    Ideguchi H; Ohno S; Ishigatsubo Y
    J Clin Rheumatol; 2007 Apr; 13(2):73-8. PubMed ID: 17414533
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of noninvasive screening tools for hepatic fibrosis, association with methotrexate cumulative dose, and risk factors in psoriasis patients.
    Lee JHM; Loo CH; Tan WC; Lee CK; Jamil A; Khor YH
    Dermatol Ther; 2022 Jan; 35(1):e15203. PubMed ID: 34779102
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hepatic and hematological adverse effects of long-term low-dose methotrexate therapy in rheumatoid arthritis: An observational study.
    Dubey L; Chatterjee S; Ghosh A
    Indian J Pharmacol; 2016; 48(5):591-594. PubMed ID: 27721549
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Real-World Outcomes Associated With Methotrexate, Sulfasalazine, and Hydroxychloroquine Triple Therapy Versus Tumor Necrosis Factor Inhibitor/Methotrexate Combination Therapy in Patients With Rheumatoid Arthritis.
    Curtis JR; Palmer JL; Reed GW; Greenberg J; Pappas DA; Harrold LR; Kremer JM
    Arthritis Care Res (Hoboken); 2021 Aug; 73(8):1114-1124. PubMed ID: 32374918
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Suboptimal methotrexate use in rheumatoid arthritis patients in Italy: the MARI study.
    Idolazzi L; Adami S; Capozza R; Bianchi G; Cozzolongo A; Epis O; Fusaro E; Lapadula G; Migliore A; Pellerito R; Pucino A; Sinigaglia L; Visalli E; Rossini M
    Clin Exp Rheumatol; 2015; 33(6):895-9. PubMed ID: 26690890
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Safety of methotrexate in rheumatoid arthritis: a retrospective cohort study in clinical practice].
    La Montagna G; Tirri R; Vitello R; Malesci D; Buono R; Mennillo G; Valentini G
    Reumatismo; 2006; 58(4):261-7. PubMed ID: 17216014
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.